



## UNITED STATES DEPARTMENT OF COMMERCE

## Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARK  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
10/041,688	01/07/02	Zhu	LOMAU-143A

## EXAMINER

Isis Ghalia

ART UNIT	PAPER NUMBER
1615	

## DATE MAILED:

## INTERVIEW SUMMARY

All participants (applicant, applicant's representative, PTO personnel):

(1) Mr. Rose Thissen (Attorney) (3)(2) Isis Ghalia (Examiner) (4)Date of Interview 06/29/06Type:  Telephonic  Televideo Conference  Personal (copy is given to  applicant  applicant's representative).Exhibit shown or demonstration conducted:  Yes  No If yes, brief description: \_\_\_\_\_Agreement  was reached.  was not reached.Claim(s) discussed: claims 1,12Identification of prior art discussed: '193Description of the general nature of what was agreed to if an agreement was reached, or any other comments: Mr. Thissen clarified

the difference between '193 and the present claims regarding the encapsulation of the active agent because US 193 encapsulate the drugs within a matrix, while the present claims are coating forming the shell over the active agent. The examiner suggested define the shell

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

 It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary. A FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

Examiner Note: You must sign this form unless it is an attachment to another form.

as coating on the active agent as disclosed in page 13, 1<sup>st</sup> paragraph of the spec. Mr. Thissen will consider the suggestion.

FORM PTOL-413 (REV. 2-98) Patentability will be determined upon filing the response. Also 112 issue discussed, will be addressed